1.Oh HJ, Yang DM, Kim CH, Jeon JG, Jung NH, Kim CY, et al. Exploring mortality rates for major causes of death in Korea. Open Public Health J 2019;12:16-25.
4.Bekele S, Yohannes T, Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Du-rame General Hospital in Southern Nations, Nationalities, and People's Region. Diabetes Metab Syndr Obes 2017;10:265-71.
6.Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-anal-ysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-15.
7.Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am 2005;34:49-62.
8.Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism 2014;63:1469-79.
10.Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem 2018;440:167-87.
11.Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, et al. Adherence to statin treatment following a myocardial infarction: an Italian population-based sur-vey. Clinicoecon Outcomes Res 2015;7:273-80.
12.Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
13.Zhang L, Wang W, Man F, Pan Q, Guo L. The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome Cardiovasc Drugs Ther 2022. [Epub ahead of print].
14.Sposito AC, Carvalho LS, Cintra RM, Araújo AL, Ono AH, Andrade JM, et al. Rebound inflammatory response during the acute phase of myocardial infarction after sim-vastatin withdrawal. Atherosclerosis 2009;207:191-4.
17.Tsalamandris C, Panagiotopoulos S, Allen TJ, Waldrip L, Van Gaal B, Goodall I, et al. Long-term intraindividual variability of serum lipids in patients with type I and type II diabetes. J Diabetes Complications 1998;12:208-14.
18.Bardini G, Dicembrini I, Rotella CM, Giannini S. Lipids seasonal variability in type 2 diabetes. Metabolism 2012;61:1674-7.
20.Lee SH, Kim HS, Park YM, Kwon HS, Yoon KH, Han K, et al. HDL-cholesterol, its variability, and the risk of diabetes: a nationwide population-based study. J Clin Endocrinol Metab 2019;104:5633-41.
22.Kreger BE, Odell PM, D'Agostino RB, Wilson PF. Long-term intraindividual cholesterol variability: natural course and adverse impact on morbidity and mortality-the Framingham Study. Am Heart J 1994;127:1607-14.
23.Hsu WH, Lai CW, Chen SC, Chiou HC, Hsiao PJ, Shin SJ, et al. Greater low-density lipoprotein cholesterol variability increases the risk of cardiovascular events in patients with type 2 diabetes mellitus. Endocr Pract 2019;25:918-25.
29.Li L, Wang F, Xu M, Lu JL, Zhao ZY, Li M, et al. Association of visit-to-visit variabilities in metabolic factors with chronic kidney disease in Chinese adults living in Shang-hai. Biomed Environ Sci 2021;34:761-72.
30.Chang YH, Chang DM, Lin KC, Hsieh CH, Lee YJ. High-density lipoprotein cholesterol and the risk of ne-phropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2013;23:751-7.
31.Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Geno-vese S, Pontremoli R, et al. Variability in HbA
1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab 2017;19:1570-8.
34.Epstein M, Vaziri ND. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012;8:214-23.
36.Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation 2018;138:2627-37.
37.Smit RAJ, Jukema JW, Postmus I, Ford I, Slagboom PE, Heijmans BT, et al. Visit-to-visit lipid variability: clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics. J Clin Lipidol 2018;12:266-76.e3.
38.Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol 2015;65:1539-48.
39.Keating AJ, Campbell KB, Guyton JR. Intermittent non-daily dosing strategies in patients with previous statin-in-duced myopathy. Ann Pharmacother 2013;47:398-404.
40.Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, et al. Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data. JAMA Cardiol 2019;4:59-63.